Anteris Technologies Global Corp. AVR 深 滬
等待開盤 11-26 09:30:00 美东时间
3.85
+0.120
+3.22%
華盛通- 最 高3.89
- 今 開3.80
- 成交量 10.55万股
- 最 低 3.66
- 昨 收 3.73
- 總市值 1.59亿
- 52周最高 8.79
- 市盈率 靜 --
- 換手率 0.26%
- 52周最低 2.34
- 委 比 81.08%
- 總股本 4119.76万
- 歷史最高 8.79
- 量 比 0.93
- 振 幅 6.17%
- 歷史最低 2.34
- 每 手 1
- 風險率 1.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Anteris Technologies Reports Q3 2025 Progress and Financials
Anteris Technologies Global Corp. ( ($AVR) ) has released its Q3 earnings. Here...
11-24 11:50
Anteris Highlights 100% Technical Success In Last 50 DurAVR THV Implants And No Valve Related Mortality At 30 Days
30-day Results Highlights for 100 DurAVR THV PatientsDurAVR THV delivered a favorable hemodynamic profile with a large EOA of 2.2 ± 0.3 cm2 and a single digit mean pressure gradient (MPG) of 8.2 ± 3.1
11-17 19:04
Anteris Announces Results for the Third Quarter of 2025
Anteris reported Q3 2025 financial results, highlighting FDA and European approvals for the PARADIGM Trial, patient recruitment progress, operational readiness enhancements, and $59.3 million net cash outflow. Key focus areas included regulatory advancement, clinical trial preparation, and manufacturing scale-up.
11-12 22:52
Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year
Anteris Technologies Global Corp. announced one-year clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV) in patients with symptomatic severe aortic stenosis and small aortic annuli. The DurAVR® system demonstrated favorable hemodynamics, including an effective orifice area (EOA) of 2.1 ± 0.2 cm² and a mean pressure gradient (MPG) of 8.6 ± 2.6 mmHg, with no moderate or severe paravalvular leaks or valve-related mortality. At 30 days,...
10-28 22:08
Anteris Technologies Requests Voluntary Suspension of Securities
The latest update is out from Anteris Technologies ( ($AU:AVR) ). Anteris Techn...
10-28 10:18
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
Anteris Technologies Global Corp. announced the initiation of the PARADIGM Trial, a global pivotal study evaluating the DurAVR® Transcatheter Heart Valve (THV) for patients with severe calcific aortic stenosis. The first patients have been enrolled and successfully treated in this trial, conducted by Prof. Dr. Ole De Backer at Copenhagen University Hospital. The PARADIGM Trial aims to compare the safety and efficacy of DurAVR® THV with commercial...
10-27 21:43
Anteris Technologies To Present One-Year Clinical Outcomes With DurAVR Transcatheter Heart Valve, At TCT 2025
Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR))), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore
10-27 20:47
Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
Anteris Technologies Global Corp. announced that Dr. Rishi Puri will present one-year clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV) at TCT 2025 in San Francisco. The presentation focuses on the DurAVR® system in patients with small aortic annuli, highlighting encouraging results from over 100 patients. The company plans to further evaluate these outcomes in the PARADIGM Trial, a prospective randomized controlled trial comparin...
10-27 12:43
Anteris Technologies Announces Share Sale Agreement
Anteris Technologies Global Corp. ( ($AVR) ) just unveiled an update. On Octobe...
10-25 05:27
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers iBio (NASDAQ:IBIO) stock increased by 28.8% to $1.15 during Monday's a...
10-21 05:08
